Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition contains pemafibrate, a salt thereof or a solvate thereof in an amount of 0.017 to 4.2 mass % in terms of a free form of pemafibrate with respect to the total mass of the pharmaceutical composition.
Abstract: The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.
Type:
Grant
Filed:
April 11, 2017
Date of Patent:
September 12, 2023
Assignee:
GW RESEARCH LIMITED
Inventors:
Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Rafael Maldonado, Daniela Parolaro, Livio Luongo, Joanna Neill
Abstract: Disclosed are an Inonotus Obliquus dextran, a preparation method and application thereof, and relates to the field of medicines. The dextran has a structural formula as follows: By optimizing the extraction and isolation process, the present disclosure obtains an Inonotus Obliquus dextran, which is structurally determined to be a new polysaccharide. The Inonotus Obliquus dextran prepared by the present disclosure is combined with gemcitabine hydrochloride to inhibit tumor cells with anti-tumor activity against pancreatic cancer, in addition to reduce the dosage of chemotherapeutic drugs as well as the adverse effects of chemotherapeutic drugs.
Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I)·0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.
Type:
Grant
Filed:
March 27, 2017
Date of Patent:
September 5, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Kentaro Iwata, Masahiro Mizuno, Kazuhiro Maeda, Tsuneo Yasuma, Misaki Homma, Yuya Oguro, Naohiro Taya, Lei Zhu, John Daniel Bailey, Marianne Langston, Siddhesh Dinanath Patil, Shruti Gour, Lilly Roy
Abstract: The invention provides methods of treatment of non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine, such as CV-8972 and CV-8814.
Abstract: Provided is a blood flow improver which is safe and has a mild action. The blood flow improver comprises S-1-propenylcysteine or a salt thereof as an active ingredient.
Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine or its pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
Abstract: The invention relates to novel methods for synthesizing amanitin derivatives having a hydroxy group attached to the central tryptophan moiety. The invention furthermore relates to novel amanitin derivatives having a hydroxy group attached to position 4?, 5? or 7? of the central tryptophan moiety, novel conjugates of such amanitin derivatives, and pharmaceutical compositions comprising such conjugates.
Type:
Grant
Filed:
January 13, 2021
Date of Patent:
July 18, 2023
Assignee:
Heidelberg Pharma Research GmbH
Inventors:
Christian Lutz, Werner Simon, Susanne Werner-Simon, Christoph Müller, Torsten Hechler, Michael Kulke
Abstract: The present invention provides an edible blended vegetable oil for reducing blood lipids and cholesterol. The trace elements in the edible blended vegetable oil include 15-300 mg/kg of polyphenols, 290-1700 mg/kg of ?-sitosterol, 260-1500 mg/kg of campesterol, 150-1000 mg/kg of stigmasterol, 140-600 mg/kg of squalene, 50-160 mg/kg of parkerol, 40-120 mg/kg of ?-tocotrienol. The prepared edible blended vegetable oil of the present invention can achieve the effect of reducing blood lipids and cholesterol through a synergistic effect within the trace elements and a reasonable ratio within fatty acids. It is suitable for people with different health needs and has a broad market prospect and application value.
Abstract: Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.
Type:
Grant
Filed:
October 16, 2014
Date of Patent:
July 4, 2023
Assignee:
Brigham Young University
Inventors:
Paul B. Savage, Carl A. Genberg, Michael D. Triplett
Abstract: The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.
Type:
Grant
Filed:
December 5, 2019
Date of Patent:
June 27, 2023
Assignee:
ABS Development 1, Inc.
Inventors:
Scott K. Thompson, Aranapakam Venkatesan, Tony Priestley, Mrinal Kundu, Ashis Saha
Abstract: The disclosed wound-healing formulation adds ingredients from the group consisting of camphor, menthol and eucalyptus to known silver sulfadiazine-based formulations, or to known silver sulfadiazine-and-urogastrone-based formulations, preferably for the topical treatment of skin wounds such as cuts, burns, surgical wounds, etc. Preferred embodiments are in cream form. The disclosed formulation shows unexpected and startling improvement in wound healing rates over expected healing rates using the known silver sulfadiazine-based or silver sulfadiazine-and-urogastrone-based formulations alone.
Abstract: The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).
Type:
Grant
Filed:
September 14, 2021
Date of Patent:
June 13, 2023
Assignee:
Arena Pharmaceuticals, Inc.
Inventors:
Antonio Garrido Montalban, Daniel J. Buzard, John A. DeMattei, Tawfik Gharbaoui, Stephen R. Johannsen, Ashwin M. Krishnan, Young Mi Kuhlman, You-An Ma, Michael John Martinelli, Suzanne Michiko Sato, Dipanjan Sengupta
Abstract: The method comprising melting a composition of matter comprising paraffin wax, mineral oil, aloe vera and CBD, placing a body member into said melted composition several times, withdrawing the body member from said composition, allowing the composition to solidify on the body member and peeling the solidified composition from said body member, said composition being solid, non-tacky, non-sticky and essentially non-material depositing at room temperature.
Abstract: Provided are a composition for treating atopic dermatitis including an herbal medicine mixed extract, and more particularly, a pharmaceutical composition, a food composition, a quasi-drug composition, and a cosmetic composition for preventing or treating atopic dermatitis, each composition including a mixed extract of Phellodendri Cortex, Schizonepetae Spica, Sophorae Radix, Glycyrrhizae Radix, Liriopis Tuber, and Radix Rehmanniae Exsiccate or a fraction thereof, and a method of treating atopic dermatitis using the pharmaceutical composition. The complex herbal medicine extract of the present invention may prevent, ameliorate, and treat atopic dermatitis to a degree similar or superior to those of the known therapeutic agents for atopic dermatitis.
Type:
Grant
Filed:
September 1, 2017
Date of Patent:
June 6, 2023
Assignee:
K-LAB Corp.
Inventors:
Seong-Gyu Ko, Inhwa Choi, Younghee Yun, Se Hyang Hong, Jin Mo Ku
Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).
Type:
Grant
Filed:
October 6, 2021
Date of Patent:
May 23, 2023
Assignee:
SUN YAT-SEN UNIVERSITY
Inventors:
Weiwei Su, Chong Liu, Qian Zhou, Peibo Li, Wei Peng, Yonggang Wang
Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.
Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
Type:
Grant
Filed:
May 14, 2021
Date of Patent:
May 9, 2023
Assignee:
THERAVANCE BIOPHARMA R&D IP, LLC
Inventors:
Melissa Fleury, Adam D. Hughes, Anne-Marie Beausoleil, Erik Fenster, Venkat R. Thalladi, Miroslav Rapta